WEBULL
News
HRTX
1.270
-7.97%
-0.110
Weekly Report: what happened at HRTX last week (1208-1212)?
Weekly Report · 3d ago
Weekly Report: what happened at HRTX last week (1201-1205)?
Weekly Report · 12/08 09:41
Roth Capital healthcare analyst holds an analyst/industry conference call
TipRanks · 12/05 19:40
Heron Therapeutics announces APONVIE inclusion in PONV guidelines
TipRanks · 12/04 13:20
Heron Therapeutics Includes APONVIE Injectable Emulsion In Guidelines For Postoperative Nausea, Vomiting
Benzinga · 12/04 13:17
HERON THERAPEUTICS ANNOUNCES INCLUSION OF APONVIE® (APREPITANT) INJECTABLE EMULSION IN THE NEWLY RELEASED FIFTH CONSENSUS GUIDELINES FOR THE MANAGEMENT OF POSTOPERATIVE NAUSEA AND VOMITING (PONV)
Reuters · 12/04 13:16
Weekly Report: what happened at HRTX last week (1124-1128)?
Weekly Report · 12/01 09:39
Weekly Report: what happened at HRTX last week (1117-1121)?
Weekly Report · 11/24 09:42
Weekly Report: what happened at HRTX last week (1110-1114)?
Weekly Report · 11/17 09:42
Validea James P. O'Shaughnessy Strategy Daily Upgrade Report - 11/13/2025
NASDAQ · 11/13 09:45
Weekly Report: what happened at HRTX last week (1103-1107)?
Weekly Report · 11/10 09:41
Heron Therapeutics Inc. Files Initial Statement of Beneficial Ownership for Director Thomas Cusack
Reuters · 11/07 14:31
Heron Therapeutics: Stagnant Cash Cow, Blockbuster That Wasn't - Steer Clear
Seeking Alpha · 11/06 22:08
Heron Therapeutics Reports Strong Q3 2025 Revenue Growth
TipRanks · 11/05 05:10
Heron Therapeutics’ Earnings Call: Growth Amid Challenges
TipRanks · 11/05 01:06
Positive Outlook for Heron Therapeutics Driven by Zynrelef and Aponvie Growth
TipRanks · 11/04 20:55
Heron Therapeutics price target lowered to $5 from $6 at Jefferies
TipRanks · 11/04 20:50
Heron Therapeutics outlines $153M–$163M net revenue target as acute care momentum accelerates
Seeking Alpha · 11/04 20:27
Heron Therapeutics: Buy Rating Affirmed Amid Promising Product Developments and Underappreciated Market Potential
TipRanks · 11/04 18:15
Promising Growth and Strategic Initiatives Justify Buy Rating for Heron Therapeutics
TipRanks · 11/04 16:45
More
Webull provides a variety of real-time HRTX stock news. You can receive the latest news about Heron Therapeutics Inc through multiple platforms. This information may help you make smarter investment decisions.
About HRTX
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. It creates and commercializes a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. Its acute care product portfolio includes ZYNRELEF and APONVIE. Its oncology care product portfolio includes CINVANTI and SUSTOL. ZYNRELEF is a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. APONVIE is an intravenous formulation of a substance P/neurokinin-1 (NK1) receptor antagonist indicated for postoperative nausea and vomiting (PONV). CINVANTI is an IV formulation of aprepitant, a substance NK1 receptor antagonist. SUSTOL is an extended-release 5-HT3 receptor antagonist for the prevention of acute and delayed nausea and vomiting.